Amarin Corporation plc announced that the Company?s Board of Directors has appointed Aaron Berg, currently Amarin?s Executive Vice President and President of the U.S. Business, as Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as CEO of the Company. Mr. Berg joined Amarin in November 2012 and has more than 30 years of biopharmaceutical industry experience.

Mr. Berg initially served as Amarin?s Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management.

Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion. Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for $3.7 billion.